We are live on ! Find out more
IMNM icon

Immunome

35 hedge funds and large institutions have $19.7M invested in Immunome in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more capital inflows, than outflows

Capital inflows: $4.38M | Capital outflows: $1.41M

56% more call options, than puts

Call options by funds: $474K | Put options by funds: $304K

3.42% more ownership

Funds ownership: 15.95% → 19.37% (+3.4%)

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
10
Closed
9
Calls
$474​K
Puts
$304​K
Net Calls
+$170​K
Net Calls Change
+$121​K

IMNM Hedge Fund Activity: Q3 2023 in Review

35 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2023, worth a combined $19.7M — up 27% from $15.4M a quarter earlier.

Fund positioning in IMNM was balanced in Q3 2023: 9 funds opened new positions, 9 closed out, 6 added to existing stakes and 10 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $1.28M. The largest seller was Cerity Partners, exiting entirely with an estimated $531K sold.

  • 35 institutional investors held Immunome (IMNM) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $19.7M of Immunome stock for Q3 2023, up 27% quarter-over-quarter.
  • 9 funds opened new Immunome positions in Q3 2023 and 9 closed out, a net change of 0 holders.
  • The largest Immunome buyer in Q3 2023 was T. Rowe Price Associates, an estimated $1.28M added.
  • The largest Immunome seller in Q3 2023 was Cerity Partners, an estimated $531K sold.

Based on aggregated 13F filings for Q3 2023.